Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XZ1D
|
|||
| Drug Name |
BLU-554
|
|||
| Synonyms |
MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
Click to Show/Hide
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | |
| Company |
Blueprint Medicines Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H24Cl2N4O4
|
|||
| Canonical SMILES |
COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)NC4COCCC4NC(=O)C=C)Cl)OC
|
|||
| InChI |
1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
|
|||
| InChIKey |
MGZKYOAQVGSSGC-DLBZAZTESA-N
|
|||
| CAS Number |
CAS 1707289-21-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FGFR4 messenger RNA (FGFR4 mRNA) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | PI3K Cascade | |||
| PIP3 activates AKT signaling | ||||
| FGFR4 ligand binding and activation | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Phospholipase C-mediated cascade | ||||
| FRS-mediated FGFR4 signaling | ||||
| SHC-mediated cascade:FGFR4 | ||||
| PI-3K cascade:FGFR4 | ||||
| Negative regulation of FGFR4 signaling | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
| PIP3 activates AKT signaling | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.